Savara (SVRA) Common Equity (2010 - 2026)
Savara (SVRA) reported Common Equity of $176.0 million for Q1 2026, up 19.07% year-over-year from $147.8 million in Q1 2025, and up 202443.68% quarter-over-quarter from -$87000.0 in Q4 2025.
Savara (SVRA) Common Equity (2010 - 2026) Analysis & Trends
Savara (SVRA) has 17 years of Common Equity data on file, last reported at $176.0 million in Q1 2026.
- Common Equity for Q1 2026 came in at $176.0 million, up 19.07% year-over-year; the trailing twelve-month figure through Mar 2026 was $176.0 million (up 19.07% YoY), and the FY2025 annual result was -$87000.0, down 100.05% from the prior year.
- Common Equity climbed to $176.0 million in Q1 2026 per SVRA's latest filing, from -$87000.0 in the prior quarter.
- Over five years, Common Equity peaked at $199.3 million in Q3 2024 and troughed at -$271000.0 in Q4 2023.
- A 5-year average of $114.9 million and a median of $120.5 million in 2025 frame the typical range for Common Equity.
- The sharpest annual moves came in 2023 and 2024: Common Equity plunged 100.25% in 2023, then soared 63365.31% in 2024.
- A 5-year view of Common Equity shows it stood at $107.8 million in 2022, then slumped by 100.25% to -$271000.0 in 2023, then soared by 63365.31% to $171.4 million in 2024, then tumbled by 100.05% to -$87000.0 in 2025, then jumped by 202443.68% to $176.0 million in 2026.
- Business Quant data shows SVRA's Common Equity at $176.0 million in Q1 2026, -$87000.0 in Q4 2025, and $94.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 35.63 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -1.42 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 13.21 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 14.38 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 11.87 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 19.36 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Savara | 1.39 Bn | 1.39 Bn | - | 176.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 176.04 Mn |
| Dec 31, 2025 | -87,000.00 |
| Sep 30, 2025 | 94.39 Mn |
| Jun 30, 2025 | 120.48 Mn |
| Mar 31, 2025 | 147.85 Mn |
| Dec 31, 2024 | 171.45 Mn |
| Sep 30, 2024 | 199.35 Mn |
| Jun 30, 2024 | 101.73 Mn |
| Mar 31, 2024 | 121.86 Mn |
| Dec 31, 2023 | -271,000.00 |
| Sep 30, 2023 | 146.54 Mn |
| Jun 30, 2023 | 87.72 Mn |
| Mar 31, 2023 | 98.26 Mn |
| Dec 31, 2022 | 107.78 Mn |
| Sep 30, 2022 | 116.51 Mn |
| Jun 30, 2022 | 127.04 Mn |
| Mar 31, 2022 | 136.48 Mn |
| Dec 31, 2021 | 144.50 Mn |
| Sep 30, 2021 | 155.23 Mn |
| Jun 30, 2021 | 165.38 Mn |